In this peptide stack, IGF-1 LR3 is the modified version of the naturally occurring peptide hormone, IGF-1
In research communities, these peptides are often discussed as complementary rather than directly competitive because: GHK-Cu is often chosen for collagen, skin, scar, and cosmetic tissue remodeling goals BPC-157 is often chosen for tendon, ligament, joint, muscle, and deeper recovery goals For that reason, many researchers discussing GHK-Cu vs BPC-157 eventually decide the better question is not which one is better, but which one better matches the tissue target? If you are building a broader research setup, you may also want to browse our research peptide collection for compatible inventory planning
How do they know where to go and what to do
Options include: Changing from one oral tablet formulation to another with different excipients Discussing sublingual preparations as an alternative (though evidence doesn't suggest superior absorption to oral tablets) For those on injections, checking the specific product's SmPC for excipient information In the UK, hydroxocobalamin injection is the licensed first-line treatment for B12 deficiency requiring parenteral therapy
Ensure they perform baseline testing (GH stimulation, IGF-1), demonstrate reconstitution techniques, and supervise dose titration
